Claims
- 1. A method for the treatment and/or prophylaxis of eating disorders in which blood glucose levels are elevated in a human or non-human mammal, which comprises administering to said human or non-human mammal in need thereof, an effective, non-toxic amount of a compound of formula (I) to lower such blood glucose levels: ##STR93## or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, wherein:
- A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group;
- R.sup.1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;
- R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3 together represent a bond;
- A.sup.2 represents a benzene ring having in total up to five substituents; and
- n represents an integer in the range of from 2 to 6.
- 2. A method according to claim 1, wherein A.sup.1 in the compound of formula (I) represents a substituted or unsubstituted, single or fused ring aromatic heterocyclyl group comprising up to 4 hetero atoms in the ring selected from oxygen, sulphur or nitrogen.
- 3. A method according to claim 1, wherein A.sup.1 in the compound of formula (I) represents a moiety of formula (a), (b) or (c): ##STR94## wherein: R.sup.4 and R.sup.5 each independently represents a hydrogen atom, an alkyl group or a substituted or unsubstituted aryl group or when R.sup.4 and R.sup.5 are each attached to a carbon atom, then R.sup.4 and R.sup.5 together with the carbon atoms to which they are attached form a benzene ring wherein each carbon atom represented by R.sup.4 and R.sup.5 together may be substituted or unsubstituted; and in the moiety of formula (a) X represents oxygen or sulphur.
- 4. A method according to claim 3, wherein R.sup.4 and R.sup.5 in (a), (b) or (c) each independently represent hydrogen, alkyl or a substituted or unsubstituted phenyl group.
- 5. A method according to claim 3, wherein R.sup.4 and R.sup.5 in (a), (b) or (c) together represent a moiety of formula (d): ##STR95## wherein R.sup.6 and R.sup.7 each independently represent hydrogen, halogen, substituted or unsubstituted alkyl or alkoxy.
- 6. A method according to claim 5, wherein R.sup.6 and R.sup.7 in (d) each represent hydrogen.
- 7. A method according to claim 1, wherein A.sup.2 in the compound of formula (I) represents a moiety of formula (e): ##STR96## wherein R.sup.8 and R.sup.9 each independently represent hydrogen, halogen, substituted or unsubstituted alkyl or alkoxy.
- 8. A method according to claim 7, wherein R.sup.8 and R.sup.9 in (e) each represent hydrogen.
- 9. A method according to claim 1, of formula (II): ##STR97## or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, wherein A.sup.1, R.sup.1, R.sup.2, R.sup.3 and n are as defined in relation to formula (I) in claim 1 and R.sup.8 and R.sup.9 are as defined in relation to formula (e) in claim 7.
- 10. A method according to claim 1, wherein n in the compound of formula (I) represents an integer 2 or 3.
- 11. A method according to claim 1, wherein R.sup.1 in the compound of formula (I) represents a methyl group.
- 12. A method according to claim 1 which comprises the administration of a compound selected from the group consisting of:
- 5-(4-[2-(N-methyl-N-(2-benzothiazolyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-(2-benzothiazolyl)amino)ethoxy]benzylidene)-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-(2-benzoxazolyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-(2-benzoxazolyl)amino)ethoxy]benzylidene)-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-(2-pyrimidinyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-(2-pyrimidinyl)amino)ethoxy]benzylidene)-2,4-thiazolidinedione;
- 5-(4-(2-(N-methyl-N-[2-(4,5-dimethylthiazolyl)]amino)ethoxy)benzyl)-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-[2-(4,5-dimethylthiazolyl)]amino)ethoxy]benzylidene)-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-(2-thiazolyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione
- 5-(4-[2-(N-methyl-N-(2-thiazolyl)amino)ethoxy]benzylidene)-2,4-thiazolidinedione;
- 5-[4-(2-(N-methyl-N-(2-(4-phenylthiazolyl))amino)ethoxy)benzyl]-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-(2-(4-phenylthiazolyl))amino)ethoxy]benzylidene)-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-[2-(4-phenyl-5-methylthiazolyl)]amino)ethoxy]benzyl)-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-[2-(4-phenyl-5-methylthiazolyl)]amino)ethoxy]benzylidene)-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-[2-(4-methyl-5-phenylthiazolyl)]amino)ethoxy]benzyl)-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-[2-(4-methyl-5-phenylthiazolyl)]amino)ethoxy]benzylidene)-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-[2-(4-methylthiazolyl)]amino)ethoxy]benzyl)-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-[2-(4-methylthiazolyl)]amino)ethoxy]benzylidene)-2,4-thiazolidinedione;
- 5-[4-(2-(N-methyl-N-[2-(5-phenyloxazolyl)]amino)ethoxy)benzyl]-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-[2-(5-phenyloxazolyl)]amino)ethoxy]benzylidene)-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-[2-(4,5-dimethyloxazolyl)]amino)ethoxy]benzyl)-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-[2-(4,5-dimethyloxazolyl)]amino)ethoxy]benzylidene)-2,4-thiazolidinedione;
- 5-[4-(2-(2-pyrimidinylamino)ethoxy)benzyl]-2,4-thiazolidinedione;
- 5-[4-(2-(2-pyrimidinylamino)ethoxy)benzylidene]-2,4-thiazolidinedione;
- 5-(4-[2-(N-acetyl-N-(2-pyrimidinyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione;
- 5-(4-(2-(N-(2-benzothiazolyl)-N-benzylamino)ethoxy)benzylidene)-2,4-thiazolidinedione;
- 5-(4-(2-(N-(2-benzothiazolyl)-N-benzylamino)ethoxy)benzyl)-2,4-thiazolidinedione;
- 5-(4-[3-(N-methyl-N-(2-benzoxazolyl)amino)propoxy]benzyl)-2,4-thiazolidinedione;
- 5-(4-[3-(N-methyl-N-(2-benzoxazolyl)amino)propoxy]benzylidene)-2,4-thiazolidinedione;
- 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzylidene)-2,4-thiazolidinedione;
- 5-(4-[4-(N-methyl-N-(2-benzoxazolyl)amino)butoxy]benzylidene)-2,4-thiazolidinedione;
- 5-(4-[4-(N-methyl-N-(2-benzoxazolyl)amino)butoxy]benzyl)-2,4-thiazolidinedione;
- 5-(4-[2-(N-(2-benzoxazolyl)amino)ethoxy]benzylidene)-2,4-thiazolidinedione;
- 5-(4-[2-(N-(2-benzoxazolyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione; and
- 5-(4-[2-(N-isopropyl-N-(2-benzoxazolyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione; or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof.
- 13. A method according to claim 1, wherein the compound is 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione.
- 14. A method according to claim 12, wherein the compound is 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione.
Priority Claims (3)
Number |
Date |
Country |
Kind |
8720825 |
Sep 1987 |
GBX |
|
8727987 |
Nov 1987 |
GBX |
|
8802454 |
Feb 1988 |
GBX |
|
Parent Case Info
This application is a continuation of application Ser. No. 08/358,327, filed Dec. 19, 1994, which is a continuation of application Ser. No. 053,997, filed Apr. 26, 1993, which in turn is a continuation-in-part of U.S. application Ser. No. 641,474, filed Jan. 15, 1991, which in turn is a continuation-in-part of U.S. application Ser. No. 457,272, filed Dec. 27, 1989, now U.S. Pat. No. 5,002,953, which in turn is a continuation-in-part of U.S. application Ser. No. 238,764, filed Aug. 30, 1988, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5232925 |
Hindley |
Aug 1993 |
|
5521201 |
Hindley |
May 1996 |
|
Continuations (2)
|
Number |
Date |
Country |
Parent |
358327 |
Dec 1994 |
|
Parent |
53997 |
Apr 1993 |
|
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
641474 |
Jan 1991 |
|
Parent |
457272 |
Dec 1989 |
|
Parent |
238764 |
Aug 1988 |
|